|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Robert_Barrow
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Project_Flow
gptkb:Project_Layla
gptkb:Project_Lucy
|
|
gptkbp:country
|
gptkb:Canada
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:18-MC_(18-methoxycoronaridine)
LSD-based therapies
psilocybin-based therapies
|
|
gptkbp:focusesOn
|
mental health treatments
psychedelic medicines
|
|
gptkbp:foundedBy
|
gptkb:JR_Rahn
gptkb:Stephen_Hurst
|
|
gptkbp:foundedYear
|
2019
|
|
gptkbp:hasPatent
|
psychedelic compounds
psychedelic delivery methods
psychedelic therapy protocols
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
gptkb:Toronto
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mind Medicine Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
gptkb:Frankfurt_Stock_Exchange
gptkb:NEO_Exchange
|
|
gptkbp:numberOfEmployees
|
50-100 (approximate, 2023)
|
|
gptkbp:partner
|
gptkb:University_Hospital_Basel
gptkb:NYU_Langone_Health
gptkb:Maastricht_University
Liechti Lab
|
|
gptkbp:researchInterest
|
gptkb:depression
addiction
ADHD
anxiety
mental health disorders
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:NEO_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:MMED
gptkb:MNMD
MMQ
|
|
gptkbp:subsidiary
|
gptkb:MindMed_Australia_Pty_Ltd
|
|
gptkbp:tradesAs
|
gptkb:MMED
gptkb:MNMD
|
|
gptkbp:website
|
https://www.mindmed.co/
|
|
gptkbp:bfsParent
|
gptkb:Bruce_Linton
|
|
gptkbp:bfsLayer
|
7
|